#United States #New York #Securities Fraud #Rosen Law Firm #PepGen Inc.

Important Update for PepGen Inc. Investors

If you purchased PepGen Inc. (NASDAQ: PEPG) securities between March 7, 2024, and March 3, 2025, this article brings necessary information regarding a potential securities fraud class action lawsuit. The Rosen Law Firm, renowned for representing investors' rights globally, has put forth details pertinent to those affected by recent developments involving PepGen.

Understanding the Class Period

Knowing the Class Period is crucial. The class action lawsuit specifically covers trades executed within the specified timeframe. The lead plaintiff deadline is set for August 8, 2025, meaning that individuals wishing to take a leadership role in this suit must file their requests with the court by then.

What You Need to Know

Individuals who purchased PepGen securities during the class period might be eligible for compensation—critical for those feeling misled by inaccurate information from the company. Importantly, no out-of-pocket costs are required to pursue this route due to the law firm's contingency fee arrangement.

Actions Steps

Follow these steps if you want to participate:
1. Visit the Rosen Law Firm's website: Take the first step by checking out this link.
2. Contact Rosen Law Firm: For more information, reach out to Phillip Kim, Esq. at 866-767-3653 or email at [email protected].
3. Know Your Rights: A class action has already been initiated, and participation serves not just personal interests but also collectively reinforces the rights of investors who may have been misled.

Why Choose Rosen Law Firm?

Selecting the right legal representation is pivotal. Rosen Law Firm has a history of successful outcomes, including the largest securities class action settlement against a Chinese company. Historically ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and in the top 4 consistently since 2013, they have recovered hundreds of millions for investors. In 2019 alone, over $438 million was secured, showcasing their expertise in the sector.

In 2020, Laurence Rosen, the founding partner, was honored as a Titan of Plaintiffs' Bar by Law360, reflecting the firm’s commitment to investor rights.

Understanding the Case Details

The legal action involves allegations that PepGen's executives made materially false and misleading statements. Key points from the lawsuit highlight:

• - The efficacy and safety of PGN-ED051 were misrepresented, leading investors to have undue confidence in the company's claims.
• - There were serious concerns regarding the CONNECT2 study, recognized as potentially dangerous, which could jeopardize the FDA approval process.
• - Due to these shortcomings, PepGen may need to halt the CONNECT2 study, casting doubt on the commercial viability of PGN-ED051.
• - Such deficiencies resulted in investors suffering losses when the reality became known.

When false details were disclosed, it significantly affected shareholder investments, prompting the collective action.

Your Legal Position

Currently, no class has been certified, meaning you are not automatically represented in this lawsuit unless you choose to retain counsel. Investors are free to stay uninvolved or actively participate as they see fit. Notably, taking lead plaintiff status does not impact recovery rights for other representative class members.

Keep Informed

Stay updated through Rosen Law Firm's social media platforms, including LinkedIn, Twitter, and Facebook, to receive the latest updates as the situation progresses. Participation in this litigation not only advances individual claims but also fosters a united front in advocating for transparency and accountability in PepGen's corporate governance.

In summary, potential plaintiffs should act swiftly to safeguard their interests in this critical matter and align with a legal team experienced in securities fraud litigation.